Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00142155 | Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia | completed | N/A | 300 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| NCT00165295 | Sildenafil Citrate in Waldenstrom's Macroglobulinemia | completed | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 27, 2011 | clinicaltrials |
| A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients |
| completed |
| Phase 2 |
| 50 |
| Janssen-Ortho Inc., CanadaINDUSTRY |
| 0 |
| Jun 21, 2011 |
| clinicaltrials |
| NCT00283439 | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With Lymphoma | completed | Phase 1 / Phase 2 | 39 | AmgenINDUSTRY | 0 | Jun 20, 2011 | clinicaltrials |
| NCT00891280 | Dose-escalation Study of Oral CX-4945 | unknown | Phase 1 | 55 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01199718 | Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 22 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01116128 | Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients(D-MP) | terminated | Phase 2 | 8 | Fondazione EMN Italy OnlusOTHER | 1 | Jun 14, 2011 | clinicaltrials |
| NCT00344422 | Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 3 | 198 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | Jun 10, 2011 | clinicaltrials |
| NCT01010880 | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 16 | Biokine Therapeutics LtdINDUSTRY | 1 | Jun 10, 2011 | clinicaltrials |
| NCT01370434 | Two Cycles of PAD Combination by AHCT in MM(PADinMM) | completed | Phase 2 | 43 | Cooperative Study Group A for HematologyNETWORK | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00398372 | Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment | completed | N/A | 500 | Stanford UniversityOTHER | 1 | Jun 2, 2011 | clinicaltrials |
| NCT00261677 | A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy | completed | Phase 3 | 224 | Ortho Biotech Products, L.P.INDUSTRY | 0 | May 23, 2011 | clinicaltrials |
| NCT00270101 | The Effect of Epoetin Alfa on the Anemia of Patients With Multiple Myeloma | completed | Phase 3 | 156 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00270166 | The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy | completed | Phase 3 | 201 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 0 | May 18, 2011 | clinicaltrials |
| NCT00216697 | An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy | completed | Phase 2 | 13 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00551798 | Prediction of the Response to Chemotherapy by Tomoscintigraphie the MIBI in the Balance Sheet Pre Hodgkin's Disease and Lymphoma Malins High Grade(MIBI) | completed | N/A | 90 | University Hospital, LimogesOTHER | 1 | May 17, 2011 | clinicaltrials |
| NCT00752518 | A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 35 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00621400 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Nantes University HospitalOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT00193505 | Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00193518 | Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 41 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00577668 | A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD) | withdrawn | Phase 2 | 0 | University of ArkansasOTHER | 1 | May 3, 2011 | clinicaltrials |
| NCT00216151 | Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma | terminated | Phase 2 | 3 | Hoosier Cancer Research NetworkOTHER | 1 | May 2, 2011 | clinicaltrials |
| NCT01341262 | THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) | completed | Phase 2 | 378 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 0 | Apr 25, 2011 | clinicaltrials |
| NCT00587912 | AIDS and Cancer Specimen Bank (ACSB) | completed | — | 65 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 21, 2011 | clinicaltrials |
| NCT01322776 | Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2011 | clinicaltrials |
| NCT01296204 | Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131(BB4) | completed | Phase 1 | 33 | Centre René GauducheauOTHER | 1 | Mar 22, 2011 | clinicaltrials |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | withdrawn | Phase 1 / Phase 2 | 20 | Charite University, Berlin, GermanyOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00290095 | Quality of Life in Patients With Multiple Myeloma | completed | — | 260 | Ullevaal University HospitalOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT00859768 | The Effectiveness of the Screening Inventory of Psychosocial Problems (SIPP) in Cancer Patients | completed | N/A | 568 | Netherlands Open UniversityOTHER | 1 | Mar 8, 2011 | clinicaltrials |
| NCT01300156 | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL) | unknown | Phase 2 | 37 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 21, 2011 | clinicaltrials |
| NCT00772811 | Using Fludarabine and Melphalan Conditioning Regimen for CLL,Lymphoma,Multiple Myeloma(Flu-Mel) | completed | Phase 2 | 38 | Cooperative Study Group A for HematologyNETWORK | 1 | Feb 17, 2011 | clinicaltrials |
| NCT00499018 | Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma(DLCL04) | unknown | Phase 3 | 399 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00774826 | Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma | unknown | Phase 3 | 534 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Feb 15, 2011 | clinicaltrials |
| NCT01296503 | Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma | completed | Phase 3 | 213 | Grupo de Estudos Multicentricos em Onco-HematologiaNETWORK | 1 | Feb 15, 2011 | clinicaltrials |
| NCT00185653 | Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma | completed | N/A | 40 | Stanford UniversityOTHER | 1 | Feb 14, 2011 | clinicaltrials |
| NCT00602511 | Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma | completed | Phase 3 | 300 | Nordic Myeloma Study GroupOTHER | 3 | Feb 9, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00509379 | Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma(LYM-2023) | completed | Phase 2 | 48 | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle LeucemieOTHER | 1 | Jan 28, 2011 | clinicaltrials |
| NCT01277172 | TREatment of degeNerative and Neoplastic Diseases With Rituximab(TREND) | unknown | Phase 2 / Phase 3 | 54 | Probiomed S.A. de C.V.INDUSTRY | 1 | Jan 14, 2011 | clinicaltrials |
| NCT01019863 | Study to Evaluate an Oxaliplatin-based Chemotherapy in Patients With Resistant or Relapsing Non-Hodgkin Lymphoma.(LNH-RGDOX) | unknown | Phase 2 | 50 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | Jan 12, 2011 | clinicaltrials |
| NCT00388635 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | completed | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT01274403 | A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma | completed | Phase 2 | 130 | Gruppo Italiano Studio LinfomiOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT00651443 | Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma | terminated | Phase 1 | 20 | BiogenINDUSTRY | 1 | Jan 7, 2011 | clinicaltrials |
| NCT00193440 | Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Dec 30, 2010 | clinicaltrials |
| NCT00193466 | Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 40 | SCRI Development Innovations, LLCOTHER | 0 | Dec 30, 2010 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT01063439 | BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL) | unknown | Phase 2 | 42 | Inje UniversityOTHER | 1 | Dec 2, 2010 | clinicaltrials |
| NCT01250808 | Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy | available | — | — | Peking UniversityOTHER | 1 | Dec 1, 2010 | clinicaltrials |
| NCT01249690 | Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma | unknown | Phase 4 | 100 | Second Military Medical UniversityOTHER | 1 | Nov 30, 2010 | clinicaltrials |
| NCT01248000 | The Use of FDG-PET in Patient With Hodgkin Lymphoma: a Population Based Study From Northern Italy | completed | — | 136 | Gruppo Italiano Studio LinfomiOTHER | 1 | Nov 25, 2010 | clinicaltrials |
Data updated 24 days agoSource updated Jun 27, 2011source: clinicaltrials